Forget needles, fat-jab PILLS are here: Why they’re cheaper, how much weight you could lose & the side effects revealed
EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the obesity epidemic. But what if there was an even easier – and cheaper – way than Ozempic-like injections, Wegovy and Mounjaro? GettySlimming tablets have been around for decades – but now scientists want to harness […]
8 Ways to Boost the Effects of Ozempic and Other GLP-1 Drug Treatments
According to leaders in obesity and nutrition research, following these key nutrition guidelines will make the most of GLP-1 drug treatment.
MAHA Agenda Excludes GLP-1 Coverage Expansion
PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo Nordisk. Although a Biden-era proposal to expand coverage was rejected due to concerns about the high cost to the federal government, […]
Regeneron pens $2B pact for Hansoh’s potential obesity rival to Lilly’s Zepbound
Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor agonist the companies believe can hold its own against Eli Lilly’s Zepbound.
Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly‘s (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years. Amid this estimated $100 billion opportunity, much smaller upstart Viking Therapeutics (NASDAQ: VKTX) has emerged with a promising clinical pipeline, aiming to […]
Mainland Chinese market for weight loss and diabetes drugs to soon be more crowded: report
2025.06.02 10:36 Novo Nordisk’s semaglutide product. Photo: Handout Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing […]
“I’m Thin, And I’m Yellow”: Doctors Sound Alarm On Concerning New Ozempic Side Effect
The “miracle weight-loss drug” Ozempic, once hailed as a shortcut to shedding pounds without the hard work, is now at the center of an alarming health scare. Dozens of Australians taking semaglutide-based medications—Ozempic, Wegovy, and Mounjaro—have come forward with reports of dr*g-induced hepatitis, a form of liver inflammation caused by medications or toxins. Some patients […]
The Ozempic Era and Shifting Obesity Blame
Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41, no. 3 (Spring 2025): 24–26. https://doi.org/10.58875/TEQC7966 Laura A. Schmidt is a professor of health policy in the School of Medicine at the University of California, San Francisco. Luc L. Hagenaars is assistant professor […]
Is Obesity Genetic or Environmental? YES!
Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific disease or trait. It involves comparing the genomes of individuals with the disease or trait to those without it to find variations that occur more frequently in the affected group. SNP […]
Predicting and Preventing Alzheimer’s Disease
This week I published an essay in the journal Science on the exciting potential to get ahead of Alzheimer’s disease. That was written a few weeks ago and several important and highly relevant reports have since been published. I’ve incorporated them in this updated version of how we can move forward to prevent this dreaded […]